minimal residual disease
Showing 1 - 25 of >10,000
Minimal Residual Disease Using Multi-omics Approach
Not yet recruiting
- Pancreatic Ductal Adenocarcinoma
- Blood collection and Pancreatic ductal adenocarcinoma minimal residual disease detection test
-
Shanghai, ChinaDepartment of Pancreatic and Hepatobiliary Surgery, Fudan Univer
Nov 29, 2023
Minimally Residual of Esophageal Cancer 001
Recruiting
- Esophageal Carcinoma
- Minimal Residual Disease
-
Shijiazhuang, Hebei, ChinaFourth Hospital of Hebei Medical University
Jul 17, 2023
MRD-tailored Therapy in Newly Diagnosed Multiple Myeloma With
Not yet recruiting
- Multiple Myeloma
- Minimal Residual Disease
- (no location specified)
Nov 1, 2023
GUIDING MULTI-MODAL THERAPIES AGAINST MINIMAL RESIDUAL DISEASE
Enrolling by invitation
- Pancreatic Adenocarcinoma
- liquid biopsy
-
Stockholm, SwedenGastrocentrum, KarolinskaUniversity Hospital
Oct 26, 2023
Next-generation Sequencing in Pediatric B-ALL Children Patients
Not yet recruiting
- Acute Lymphoblastic Leukemia, Pediatric
- (no location specified)
Apr 19, 2023
B-Cell Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia Trial in Tampa (Tecartus)
Recruiting
- B-Cell Lymphoblastic Leukemia
- Acute Lymphoblastic Leukemia
-
Tampa, FloridaMoffitt Cancer Center
Nov 28, 2023
Minimal Residual Disease Trial in Tianjin (QN-030a, Cyclophosphamid, Fludarabine)
Recruiting
- Minimal Residual Disease
- QN-030a
- +3 more
-
Tianjin, Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital
Nov 3, 2022
AML, Adult, Minimal Residual Disease Trial (MRD assessment)
Not yet recruiting
- AML, Adult
- Minimal Residual Disease
- MRD assessment
- (no location specified)
Oct 13, 2023
Stage II-III Gastric Cancer Trial in Jinan, Qingdao, Yantai (MRD-guided therapy)
Recruiting
- Stage II-III Gastric Cancer
- MRD-guided therapy
-
Jinan, Shandong, China
- +4 more
Nov 27, 2023
Ovarian Cancer Trial in Houston (Pembrolizumab, Bevacizumab, Cyclophosphamide)
Not yet recruiting
- Ovarian Cancer
- Pembrolizumab
- +2 more
-
Houston, TexasMD Anderson Cancer Center
Oct 9, 2023
Rectal Cancer Patients Based on ctDNA-MRD Technology
Recruiting
- Rectal Adenocarcinoma
- +3 more
- MRD detection
-
Guangzhou, Guangdong, ChinaWeiWei Xiao
Jul 31, 2023
Using Mass Spectrometry Detecting Minimal Residual Disease in
Recruiting
- Multiple Myeloma
-
Tianjin, ChinaInsituteHBDH
Sep 8, 2022
Lymphoma Trial in Houston (cell-free DNA)
Not yet recruiting
- Lymphoma
- cell-free DNA
-
Houston, TexasMD Anderson Cancer Center
Dec 22, 2022
Novel Digital Array PCR for Acute Myeloid Leukemia (AML)
Recruiting
- Leukemia, Myeloid, Acute
- Minimal Residual Disease
-
Chapel Hill, North CarolinaNorth Carolina Cancer Hospital (NCCH)
Feb 2, 2023
Danish Assessment of Minimal Residual Disease by Liquid Biopsies
Recruiting
- Colorectal Neoplasms
- +5 more
-
Copenhagen, Capital Region Of Denmark, Denmark
- +8 more
Oct 13, 2023
Minimal Residual Disease in Peripheral T-cell Lymphoma
Active, not recruiting
- Peripheral T Cell Lymphoma
- Tumor biopsy
- +2 more
-
Boston, Massachusetts
- +2 more
Dec 19, 2022
ctDNA-based Minimal Residual Disease Detection for Resected
Not yet recruiting
- Pancreatic Cancer Resectable
- ctDNA-based MRD detection
-
Shanghai, Shanghai, ChinaRuijin Hospital Affiliated to Shanghai Jiao Tong University Scho
Jul 29, 2022
Acute Lymphocytic Leukemia Trial (Inotuzumab ozogamicin)
Not yet recruiting
- Acute Lymphocytic Leukemia
- Inotuzumab ozogamicin
- (no location specified)
Jul 11, 2022
Esophageal Cancer Trial (Blood sample)
Not yet recruiting
- Esophageal Cancer
- Blood sample
- (no location specified)
Jan 19, 2023
Minimal Residual Disease in Gastric Cancer by Liquid Biopsy
Recruiting
- Gastric Cancer
- ctDNA
- ctDNA
-
Ho Chi Minh City, VietnamUniversity Medical Center Ho Chi Minh City
Apr 27, 2022
AML, Adult, Minimal Residual Disease Trial in Tianjin (CD33/CLL1 dual CAR-NK cell, Cyclophosphamid, Fludarabine)
Not yet recruiting
- AML, Adult
- Minimal Residual Disease
- CD33/CLL1 dual CAR-NK cell
- +5 more
-
Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital
Aug 4, 2023